Skip to main content

Table 1 Overview on HIV-2 samples analyzed

From: The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals

Subject

Clones

CD4a

PVLb

Groupc

R5/X4d

Group

vpxallelese

References

RH2-3

2C5/8A3

770

bql

aviremic

R5

A

3/3

[26–30]

RH2-13

1D4/5C1

900

bql

aviremic

R5

A

3/3

[26–30]

RH2-14

1B1/1D1

550

bql

aviremic

R5

A

3/3

[26–30]

RH2-22

2C2/1B4

670

bql

aviremic

R5

B

4/4

[26–30]

RH2-1

A8/D8

240

>500

viremic

R5

A

3/6

[26–30]

RH2-5

2D11/2F10

120

110,000

viremic

R5

A

3/3

[26–30]

RH2-7

B3/D6

10

>500

viremic

R5

A

3/3

[26–30]

RH2-21

2B2/2F9

60

59,000

viremic

n.k.

A

3/3

[26–30]

RH2-24

2F11

70

330,000

viremic

R5/X4

A

3

[26–30]

RH2-26

1C1

10

>500

viremic

R5/X4

A

8

[26–30]

PH2.1

C12/E6

200

>500

viremic

n.k.

A

3/3

[30, 31]

  1. a Absolute CD4 T cell counts per μl blood.
  2. b Copies of plasma viral RNA per milliliter.
  3. c Grouped based on VLs.
  4. d Usage of CCR5 or CXCR4 for viral entry.
  5. e Number of vpx alleles sequenced per biological HIV-2 clone.
  6. Abbreviations: PVL plasma viral load, Bql below quantifiable limit, n.k. not known.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us